| Literature DB >> 32457741 |
Charles Neu1,2,3, Philipp Baumbach1,2, Alina K Plooij1,2, Kornel Skitek1,2, Juliane Götze1,2, Christian von Loeffelholz1, Christiane Schmidt-Winter1,2, Sina M Coldewey1,2,3.
Abstract
The imbalance of oxygen delivery and oxygen consumption resulting in insufficient tissue oxygenation is pathognomonic for all forms of shock. Mitochondrial function plays an important role in the cellular oxygen metabolism and has been shown to impact a variety of diseases in the intensive care setting, specifically sepsis. Clinical assessment of tissue oxygenation and mitochondrial function remains elusive. The in vivo protoporphyrin IX-triplet state lifetime technique (PpIX-TSLT) allows the direct, non-invasive measurement of mitochondrial oxygen tension (mitoPO2) in the human skin. Our recently established measurement protocol for the Cellular Oxygen Metabolism (COMET) Monitor, a novel device employing the PpIX-TSLT, additionally allows the evaluation of oxygen consumption (mitoVO2) and delivery (mitoDO2). In the intensive care setting, these variables might provide new insight into mitochondrial oxygen metabolism and especially mitoDO2 might be a surrogate parameter of microcirculatory function. However, the feasibility of the PpIX-TSLT in critically ill patients has not been analyzed systematically. In this interim study analysis, we evaluated PpIX-TSLT measurements of 40 patients during the acute phase of sepsis. We assessed (a) potential adverse side effects of the method, (b) the rate of analyzable measurements, (c) the stability of mitoPO2, mitoVO2, and mitoDO2, and (d) potential covariates. Due to excessive edema in patients with sepsis, we specifically analyzed the association of patients' hydration status, assessed by bioimpedance analysis (BIA), with the aforementioned variables. We observed no side effects and acquired analyzable measurements sessions in 92.5% of patients (n = 37/40). Different measures of stability indicated moderate to good repeatability of the PpIX-TSLT variables within one session of multiple measurements. The determined limits of agreement and minimum detectable differences may be helpful in identifying outlier measurements. In conjunction with signal quality they mark a first step in developing a previously unavailable standardized measurement quality protocol. Notably, higher levels of hydration were associated with lower mitochondrial oxygen tension. We conclude that COMET measurements are viable in patients with sepsis. To validate the clinical and diagnostic relevance of the PpIX-TSLT using the COMET in the intensive care setting, future studies in critically ill patients and healthy controls are needed.Entities:
Keywords: COMET; cellular oxygen metabolism; critically ill patients; mitochondrial dysfunction; mitochondrial oxygen metabolism; mitochondrial oxygen tension; protoporphyrin IX-triplet state lifetime technique; sepsis
Mesh:
Substances:
Year: 2020 PMID: 32457741 PMCID: PMC7221153 DOI: 10.3389/fimmu.2020.00757
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Inclusion and exclusion criteria for the study.
| Sepsis or septic shock meeting Sepsis-3 criteria ( |
| Onset of first infection-caused organ dysfunction no longer than 72 h before enrolment |
| At least 18 years of age |
| Written informed consent from the patient, legal representative or proxy, or preliminary consent after consultation of an independent medical doctor |
| Cardiac surgery in the last 12 months |
| Significant heart disease: |
| Endocarditis |
| Higher degree valve disorders (severe valvular heart disease, symptomatic aortic valve stenosis, moderate mitral regurgitation with reduced ejection fraction) |
| Congenital heart defect (e.g., transposition of the great arteries, tetralogy of Fallot, atrioventricular septal defect) |
| Hemodynamically relevant shunting heart defect |
| Reduced cardiac output (EF < 45% or 10% below norm |
| Pulmonary arterial hypertension prior to onset of sepsis |
| Myocardial infarction 12 months prior to onset of sepsis |
| History of heart transplantation |
| Cardiopulmonary resuscitation 4 weeks prior to onset of sepsis |
| History of pneumonectomy |
| Child C liver cirrhosis |
| Contraindications for transesophageal echocardiography and insufficient quality of transthoracic echocardiography |
| Terminal chronic kidney disease with dialysis |
| Sepsis within 8 months prior to onset of sepsis |
| Pregnancy/breast-feeding |
| Therapy limitation/do-not-resuscitate order |
| Remaining life expectancy <6 months due to other causes than sepsis |
| Prior participation in this study |
| Participation in another interventional study |
Left ventricular ejection fraction >52% in men, >54% in women according to the American Society of Echocardiography and the European Association of Cardiovascular Imaging (.
Figure 1(A) Description of a single PpIX-TSLT measurement to obtain mitochondrial oxygen tension (mitoPO2), mitochondrial oxygen consumption (mitoVO2), and mitochondrial oxygen delivery (mitoDO2). (B) Illustration of the raw PpIX-TSLT data and the two sigmoid fit functions to estimate the PpIX-TSLT variables.
Figure 2Overview of the patient inclusion and analytical cohorts. Results for primary analysis are reported from the PpIX-TSLT sample. Results for Bioimpedance Analysis (BIA) and additional correlative analyses with PpIX-TSLT variables are reported for the PpIX-TSLT-BIA sample.
Demographics and clinical characteristics (n = 37 patients).
| Age | [years] | 70.00 | 58.00 | 79.00 |
| Initial SOFA increase | [points] | 5.00 | 4.00 | 7.00 |
| Body weight | [kilogram] | 76.20 | 68.00 | 92.00 |
| Body height | [meter] | 1.72 | 1.65 | 1.75 |
| BMI | [kg/m2] | 27.13 | 23.57 | 31.02 |
| Body surface | [m2] | 1.89 | 1.66 | 2.04 |
| Sex | Female | 13 | 35.1 | |
| Male | 24 | 64.9 | ||
| Sepsis focus | Pneumonia | 17 | 45.9 | |
| Intra-abdominal/ gastrointestinal | 13 | 35.1 | ||
| Thoracic | 2 | 5.4 | ||
| Urogenital | 3 | 8.1 | ||
| Bone/soft-tissue | 1 | 2.7 | ||
| Skin | 1 | 2.7 | ||
| Ventilation | Spontaneous | 20 | 54.1 | |
| Invasive/non-invasive | 17 | 45.9 | ||
| Catecholamines | None | 11 | 29.7 | |
| Medium | 11 | 29.7 | ||
| High | 15 | 40.5 |
For continuous measures median, first and third quartile (Q.
Any duration of invasive ventilation. Non-invasive ventilation > 6 h.
Dopamine > 5 μg/kg/min or epinephrine ≤ 0.1 μg/kg/min or norepinephrine ≤ 0.1 μg/kg/min.
Dopamine > 15 μg/kg/min or epinephrine > 0.1 μg/kg/min or norepinephrine > 0.1 μg/kg/min.
Descriptive statistics for PpIX-TSLT variables.
| MitoPO2 : baseline | [mmHg] | 37 | 61.86 ± 19.97 | [55.42, 68.29] | 65.15 | 49.21 | 70.84 | 16.75 | 103.30 |
| MitoPO2 : post | [mmHg] | 37 | 55.52 ± 15.64 | [50.48, 60.56] | 56.75 | 44.18 | 64.38 | 13.88 | 94.68 |
| MitoVO2 : maximum | [mmHg/s] | 37 | 4.82 ± 2.39 | [4.05, 5.59] | 4.65 | 3.16 | 5.71 | 0.00 | 9.54 |
| MitoVO2 : average | [mmHg/s] | 37 | 3.43 ± 1.71 | [2.88, 3.98] | 3.31 | 2.25 | 4.07 | 0.00 | 6.80 |
| MitoDO2 : maximum | [mmHg/s] | 37 | 6.87 ± 4.06 | [5.56, 8.18] | 5.76 | 4.23 | 7.56 | 0.00 | 12.57 |
| MitoDO2 : average | [mmHg/s] | 37 | 4.89 ± 2.89 | [3.96, 5.82] | 4.11 | 3.01 | 5.39 | 0.00 | 8.95 |
All PpIX-TSLT variables from one measurement session were averaged before descriptive analysis.
mitoPO.
Thresholds are defined as Q.
SD, standard deviation; 95%CI, 95 percent confidence interval, Q.
Intra-session stability of the PpIX-TSLT variables (n = 36 patients with at least 2 reliable PpIX-TSLT measurements).
| MitoPO2 : baseline | [mmHg] | 114 | −4.42 | ± | 13.62 | [−6.92, −1.92] | 0.75 | −31.12 | −35.27 | −28.14 | 22.28 | 19.30 | 26.43 | |||
| MitoPO2 : post | [mmHg] | 114 | −0.95 | ± | 11.24 | [−3.01, 1.11] | 0.369 | 0.72 | −22.99 | −26.41 | −20.53 | 21.09 | 18.63 | 24.51 | ||
| MitoVO2 : maximum | [mmHg/s] | 114 | −0.02 | ± | 1.54 | [−0.30, 0.26] | 0.901 | 0.81 | −3.03 | −3.50 | −2.70 | 3.00 | 2.66 | 3.47 | ||
| MitoVO2 : average | [mmHg/s] | 114 | −0.01 | ± | 1.10 | [−0.22, 0.19] | 0.893 | 0.81 | −2.16 | −2.50 | −1.92 | 2.14 | 1.90 | 2.47 | ||
| MitoDO2 : maximum | [mmHg/s] | 114 | 1.07 | ± | 3.96 | [0.34, 1.79] | 0.68 | −6.69 | −7.89 | −5.82 | 8.82 | 7.96 | 10.03 | |||
| MitoDO2 : average | [mmHg/s] | 114 | 0.76 | ± | 2.82 | [0.24, 1.28] | 0.68 | −4.76 | −5.62 | −4.14 | 6.28 | 5.66 | 7.14 | |||
Mean difference (Δmean), corresponding standard deviation (SD), and 95% confidence intervals (95%CI) for PpIX-TSLT measurement pairs are shown. Additionally, Pearson correlation coefficients (r), corresponding p-values (p.
Intraclass correlation coefficients (ICC) with corresponding 95% confidence intervals, standard error of measurement (SEM), and minimum detectable difference (MDD) for PpIX-TSLT variables (n = 36 patients with at least 2 reliable PpIX-TSLT measurements).
| MitoPO2 : baseline | 114 | 9.63 | 26.70 | [mmHg] | 0.729 | 0.612 | 0.811 | |
| MitoPO2 : post | 114 | 7.95 | 22.04 | [mmHg] | 0.717 | 0.615 | 0.796 | |
| MitoVO2 : maximum | 114 | 1.09 | 3.01 | [mmHg/s] | 0.805 | 0.729 | 0.861 | |
| MitoVO2 : average | 114 | 0.78 | 2.15 | [mmHg/s] | 0.805 | 0.729 | 0.861 | |
| MitoDO2 : maximum | 114 | 2.80 | 7.75 | [mmHg/s] | 0.652 | 0.526 | 0.749 | |
| MitoDO2 : average | 114 | 1.99 | 5.52 | [mmHg/s] | 0.652 | 0.526 | 0.749 | |
P < 0.05 are printed in bold.
ICC < 0.5 poor, 0.5 ≤ ICC ≤ 0.75 moderate, 0.75 ≤ ICC ≤ 0.90 good, ICC > 0.90 excellent (.
Main findings of the correlation analyses for the PpIX-TSLT variables and potential covariates.
| MitoPO2 : baseline | BIVA: vector length | 33 | 0.36 | 0.23 | 0.191 | |
| MitoVO2 : average | Goodness of Fit | 37 | 0.71 | 0.58 | ||
| MitoDO2 : average | Body height | 37 | −0.38 | −0.32 | 0.051 | |
| Duration of 5-ALA application | 36 | −0.37 | −0.37 | |||
| Signal Quality | 37 | −0.34 | −0.27 | 0.113 | ||
| Temperature: room | 37 | 0.40 | 0.25 | 0.140 | ||
| Signal quality | Duration of 5-ALA application | 36 | 0.35 | 0.22 | 0.198 | |
| Temperature: room | 37 | −0.34 | −0.39 |
Spearman's rank correlation coefficient (ρ) with the corresponding p-value (p.
mitoPO.
Obtained from height-standardized resistance and reactance values.